JP2015505565A5 - - Google Patents

Download PDF

Info

Publication number
JP2015505565A5
JP2015505565A5 JP2014555783A JP2014555783A JP2015505565A5 JP 2015505565 A5 JP2015505565 A5 JP 2015505565A5 JP 2014555783 A JP2014555783 A JP 2014555783A JP 2014555783 A JP2014555783 A JP 2014555783A JP 2015505565 A5 JP2015505565 A5 JP 2015505565A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
cobicistat
acceptable salt
kit
tenofovir arafenamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014555783A
Other languages
English (en)
Japanese (ja)
Other versions
JP6059255B2 (ja
JP2015505565A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/024438 external-priority patent/WO2013116720A1/en
Publication of JP2015505565A publication Critical patent/JP2015505565A/ja
Publication of JP2015505565A5 publication Critical patent/JP2015505565A5/ja
Application granted granted Critical
Publication of JP6059255B2 publication Critical patent/JP6059255B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014555783A 2012-02-03 2013-02-01 ウイルス感染の処置における使用のためのテノホビルアラフェンアミドヘミフマル酸塩とコビシスタットを含む併用療法 Active JP6059255B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201261594894P 2012-02-03 2012-02-03
US61/594,894 2012-02-03
US201261618411P 2012-03-30 2012-03-30
US61/618,411 2012-03-30
US201261624676P 2012-04-16 2012-04-16
US61/624,676 2012-04-16
US201261692392P 2012-08-23 2012-08-23
US61/692,392 2012-08-23
US201261737493P 2012-12-14 2012-12-14
US61/737,493 2012-12-14
PCT/US2013/024438 WO2013116720A1 (en) 2012-02-03 2013-02-01 Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections

Publications (3)

Publication Number Publication Date
JP2015505565A JP2015505565A (ja) 2015-02-23
JP2015505565A5 true JP2015505565A5 (https=) 2016-03-24
JP6059255B2 JP6059255B2 (ja) 2017-01-11

Family

ID=47722563

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014555783A Active JP6059255B2 (ja) 2012-02-03 2013-02-01 ウイルス感染の処置における使用のためのテノホビルアラフェンアミドヘミフマル酸塩とコビシスタットを含む併用療法

Country Status (15)

Country Link
US (2) US20150105350A1 (https=)
EP (1) EP2809323A1 (https=)
JP (1) JP6059255B2 (https=)
KR (1) KR20140119177A (https=)
CN (1) CN104105484A (https=)
AU (3) AU2013204727A1 (https=)
BR (1) BR112014018918A8 (https=)
CA (1) CA2863662A1 (https=)
EA (1) EA026138B1 (https=)
HK (2) HK1202801A1 (https=)
IL (1) IL233874A0 (https=)
MD (1) MD20140091A2 (https=)
MX (1) MX2014009172A (https=)
NZ (1) NZ629896A (https=)
WO (2) WO2013116730A1 (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009008935A (es) 2007-02-23 2009-11-02 Gilead Sciences Inc Moduladores de las propiedades farmacocineticas de productos terapeuticos.
RS53347B (sr) 2008-12-09 2014-10-31 Gilead Sciences, Inc. Modulatori toll-sličnih receptora
ES2608871T5 (es) 2011-08-16 2024-04-04 Gilead Sciences Inc Alafenamide hemifumarate de tenofovir
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
HK1220390A1 (zh) * 2013-08-29 2017-05-05 Teva Pharmaceutical Industries Ltd. 包括恩曲他滨,替诺福韦,达芦那韦和利托那韦的单位剂型以及包含达芦那韦和利托那韦的单体片剂
IN2013CH05455A (https=) * 2013-11-27 2015-08-07 Laurus Labs Private Ltd
WO2015120057A1 (en) * 2014-02-05 2015-08-13 Gilead Sciences, Inc. Pharmaceutical combinations against co-infection with hiv and tuberculosis
CA2942877A1 (en) * 2014-04-08 2015-10-15 Nitzan SHAHAR Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
CN105518011B (zh) * 2014-04-21 2018-07-27 四川海思科制药有限公司 氨基磷酸酯类衍生物制备方法及其中间体和中间体的制备方法
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
JP6522732B2 (ja) * 2014-07-11 2019-05-29 ギリアード サイエンシーズ, インコーポレイテッド Hivを治療するためのトール様受容体の調節因子
SG11201701520TA (en) 2014-09-16 2017-04-27 Gilead Sciences Inc Solid forms of a toll-like receptor modulator
CN105237571B (zh) * 2014-11-28 2018-03-09 成都苑东生物制药股份有限公司 9‑[(r)‑2‑[[(s)‑[[(s)‑1‑(异丙氧基羰基)乙基]氨基]苯氧基氧膦基]甲氧基]丙基]腺嘌呤的盐
US20180338993A1 (en) * 2014-12-04 2018-11-29 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
JP7381190B2 (ja) 2014-12-26 2023-11-15 エモリー・ユニバーシテイ N4-ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
AU2015373104B2 (en) * 2015-01-03 2020-07-09 Mylan Laboratories Limited Processes for the preparation of amorphous tenofovir alafenamide hemifumarate and a premix thereof
WO2016172342A1 (en) 2015-04-21 2016-10-27 Eiger Biopharmaceuticals, Inc. Pharmaceutical compositions comprising lonafarnib and ritonavir
CN104817593B (zh) * 2015-04-27 2016-11-16 广州同隽医药科技有限公司 半富马酸替诺福韦艾拉酚胺关键中间体的合成工艺
CA2921336A1 (en) * 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
PT4070788T (pt) * 2015-06-30 2023-06-06 Gilead Sciences Inc Formulações farmacêuticas
US9598459B2 (en) 2015-08-03 2017-03-21 Pop Test Oncology Llc Pharmaceutical compositions and methods
CN105153231A (zh) * 2015-08-28 2015-12-16 浙江车头制药股份有限公司 一种一苯基pmpa的制备方法
WO2017083304A1 (en) * 2015-11-09 2017-05-18 Gilead Sciences, Inc. Therapeutic compositions for treatment of human immunodeficiency virus
US20170232020A1 (en) * 2016-02-12 2017-08-17 Cipla Limited Pharmaceutical compositions
CN107179355B (zh) * 2016-03-11 2021-08-10 广东东阳光药业有限公司 一种分离检测替诺福韦艾拉酚胺及其有关物质的方法
EP3503895B1 (en) * 2016-08-25 2021-09-15 Merck Sharp & Dohme Corp. Antiviral prodrugs of tenofovir
CN108070003A (zh) * 2016-12-02 2018-05-25 上海博志研新药物技术有限公司 替诺福韦艾拉酚胺半反丁烯二酸盐晶型及制备方法和应用
RU2659388C1 (ru) 2017-02-28 2018-07-02 Васильевич Иващенко Александр Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение
RU2647576C1 (ru) * 2017-02-28 2018-03-16 Васильевич Иващенко Александр Циклобутил (S)-2-[[[(R)-2-(6-аминопурин-9-ил)-1-метил-этокси]метил-фенокси-фосфорил]амино]-пропаноаты, способ их получения и применения
CN106928277A (zh) * 2017-03-16 2017-07-07 江苏诚信药业有限公司 一种替诺福韦艾拉酚胺合成的工艺方法
AU2018239257B2 (en) 2017-03-20 2023-09-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HIV post-exposure prophylaxis
CN110769856A (zh) * 2017-04-18 2020-02-07 希普拉有限公司 用于治疗逆转录病毒感染的组合疗法
RU2659693C1 (ru) * 2017-06-30 2018-07-03 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция, обладающая активностью против ВИЧ-инфекции
EP3700573A1 (en) * 2017-10-24 2020-09-02 Gilead Sciences, Inc. Methods of treating patients co-infected with a virus and tuberculosis
PT3706762T (pt) 2017-12-07 2024-12-05 Univ Emory N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos
CN110305163A (zh) * 2018-03-27 2019-10-08 北京济美堂医药研究有限公司 替诺福韦艾拉酚胺半富马酸盐的制备方法
CN108484672A (zh) * 2018-05-23 2018-09-04 中国药科大学制药有限公司 磷丙替诺福韦的手性拆分方法
CN109081853A (zh) * 2018-09-03 2018-12-25 南京正大天晴制药有限公司 一种磷丙替诺福韦有关物质的制备方法
TWI810456B (zh) 2019-05-22 2023-08-01 美商基利科學股份有限公司 Tlr7調節化合物及hiv疫苗之組合
EP3989956A1 (en) * 2019-06-28 2022-05-04 Anhui Ronghang Biotech Development Co., Ltd. Compositions and methods for treatment of hepatitis b virus infection
AU2020318808A1 (en) 2019-07-19 2022-02-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HIV pre-exposure prophylaxis
CN111606949A (zh) * 2020-03-13 2020-09-01 浙江车头制药股份有限公司 一种磷丙替诺福韦杂质的制备方法
CN111303209A (zh) * 2020-03-21 2020-06-19 石家庄龙泽制药股份有限公司 一种丙酚替诺福韦降解杂质的制备方法
WO2022118020A1 (en) * 2020-12-02 2022-06-09 Cipla Limited Method of treating viral infection
WO2024196814A1 (en) 2023-03-17 2024-09-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for treatment of age-related macular degeneration
EP4640214A1 (en) * 2024-03-28 2025-10-29 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A tablet comprising tenofovir alafenamide monofumarate

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB453061A (en) 1935-03-23 1936-09-04 Charles Howard Twigg Improvements in and relating to gas heated geysers and water heaters
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US20020119443A1 (en) 2000-07-21 2002-08-29 Gilead Sciences, Inc. Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
DE10153078A1 (de) 2001-10-30 2003-05-22 Degussa Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen
DK1583542T3 (da) 2003-01-14 2008-09-22 Gilead Sciences Inc Sammensætninger og fremgangsmåder til antiviral kombinationsterapi
MX2009008935A (es) * 2007-02-23 2009-11-02 Gilead Sciences Inc Moduladores de las propiedades farmacocineticas de productos terapeuticos.
WO2009005693A1 (en) 2007-06-29 2009-01-08 Gilead Sciences, Inc. Novel hiv reverse transcriptase inhibitors
EP2393485B1 (en) * 2009-02-06 2015-07-29 Gilead Sciences, Inc. Bilayer tablets comprising elvitegravir, cobicistat, emtricitabine and tenofovir
ES2608871T5 (es) * 2011-08-16 2024-04-04 Gilead Sciences Inc Alafenamide hemifumarate de tenofovir

Similar Documents

Publication Publication Date Title
JP2015505565A5 (https=)
JP2015038149A5 (https=)
SI2932970T1 (en) Antiviral therapy
JP2016508134A5 (https=)
HRP20231018T1 (hr) Terapeutski spojevi korisni za profilaktičko ili terapijsko liječenje hiv virusne infekcije
HRP20191957T1 (hr) Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba
WO2017083304A8 (en) Therapeutic compositions for treatment of human immunodeficiency virus
JP2010532373A5 (https=)
JP2016179996A5 (https=)
JP2010532372A5 (https=)
HRP20211543T1 (hr) Derivati kinazolina koji se koriste za liječenje hiv-a
HRP20180455T1 (hr) Natrijev (2r, 5s, 13ar) -7, 9-diokso-10- ( (2,4,6-trifluorobenzil) karbamoil) -2, 3, 4, 5, 7, 9, 13, 13a-oktahidro-2, 5-metanopirido [1’,2’ : 4.5]pirazino [2,1-b]oksazepin-8-olat
JP2016527217A5 (https=)
HRP20240501T1 (hr) Derivati pirido[2,3-d]pirimidina kao inhibitori replikacije virusa humane imunodeficijencije
JP2013518124A5 (https=)
FI3865484T3 (fi) Pde9:n estäjä, jossa on imidatsopyratsinonirunko, perifeeristen sairauksien hoitoon
JP2015522018A5 (https=)
RU2013148779A (ru) Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени
JP2002528502A5 (https=)
JP2013508289A5 (https=)
JP2017503014A5 (https=)
JP2016505050A5 (https=)
WO2006044968A3 (en) Combination therapy for treating viral infections
EP4230209A4 (en) PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL COMBINED FORMULATION AND COMBINATION FORMULATION KIT FOR THE PREVENTION OR TREATMENT OF CHRONIC HEPATITIS B, EACH COMPRISING, AS ACTIVE INGREDIENT, AN ORAL ANTIVIRAL AGENT AND A THERAPEUTIC VACCINE COMPRISING A LIPOPEPTIDE AND A POLY(I) ADJUVANT :VS)
JP2023531930A5 (https=)